Trials / Unknown
UnknownNCT00546936
Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis
Ranibizumab vs PDT for Presumed Ocular Histoplasmosis
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Barnes Retina Institute · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the change in visual activity of ranibizumab to Photodynamic Therapy (PDT)in patients with choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ranibizumab | 0.5mg ranibizumab |
| DRUG | verteporfin | Photodynamic therapy with verteporfin every 3 months for 1 year |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2009-10-01
- Completion
- 2010-04-01
- First posted
- 2007-10-19
- Last updated
- 2009-04-16
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00546936. Inclusion in this directory is not an endorsement.